Moa Fransson

Immunology and Microbiology · Life Sciences

10h-index757citations22works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(12), Cancer Research and Treatments(8), CAR-T cell therapy research(5), T-cell and B-cell Immunology(4), Multiple Sclerosis Research Studies(4)

Publications22 total

Supplementary Data from <i>AdCD40L</i> Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial
2023Open Access
Data from <i>AdCD40L</i> Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial
2023Open Access
Supplementary Data from <i>AdCD40L</i> Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial
2023Open Access
Data from <i>AdCD40L</i> Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial
2023Open Access
The blood endothelial cell chamber – An innovative system to study immune responses in drug development
International Immunopharmacology·2020· 3 citedOpen Access
Mesenchymal stromal cells support endothelial cell interactions in an intramuscular islet transplantation model
Regenerative Medicine Research·2015· 20 citedOpen Access
Finding Patterns in Vehicle Diagnostic Trouble Codes : A data mining study applying associative classification
KTH Publication Database DiVA (KTH Royal Institute of Technology)·2015· 6 citedOpen Access
The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention
Journal of Neuroimmunology·2014· 33 cited
Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis
Journal of Neuroimmunology·2014
Intranasal delivery of central nervous system‐retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis
Immunology·2014· 42 citedOpen Access
T‐cell responses after haematopoietic stem cell transplantation for aggressive relapsing–remitting multiple sclerosis
Immunology·2013· 42 citedOpen Access
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
Journal of Neuroinflammation·2012· 340 citedOpen Access
<i>AdCD40L</i> Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial
Clinical Cancer Research·2010· 119 cited
T regulatory cells lacking CD25 are increased in MS during relapse
Autoimmunity·2010· 35 cited
Engineered T regulatory cells target CNS and suppress active EAE upon intra nasal delivery
2010
CNS-Targeted Cell Therapy for Multiple Sclerosis
KTH Publication Database DiVA (KTH Royal Institute of Technology)·2010Open Access
Genetically Engineered Cells Target CNS and Cure Experimental Autoimmune Encephalomyelitis
Human Gene Therapy·2010
Human Mesenchymal stromal cells expressing a CNS-targeting receptor can be administrated intra nasally and cure expersimental autoimmune enchphlomyelitis
2010
Local AdCD40L Gene Therapy is Effective for Disseminated Murine Experimental Cancer by Breaking T-cell Tolerance and Inducing Tumor Cell Growth Inhibition
Journal of Immunotherapy·2009· 20 cited
The T‐cell pool is anergized in patients with multiple sclerosis in remission
Immunology·2008· 43 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Angelica Loskog(18), Joachim Burman(8), Sara M. Mangsbo(8), Camilla A. Lindqvist(7), Thomas H. Tötterman(7), Elena Piras(5), Eva B. Brittebo(5), Per‐Uno Malmström(5), Alkwin Wanders(5), Truls Gårdmark(5), Peetra U. Magnusson(4), Jan Fagius(4), Robert A. Harris(3), Ida Rasmusson Duprez(3), Katarina LeBlanc(3), Magnus Essand(2), Emma Svensson(2), H Wang(2), Berith Nilsson(1), Binfeng Lu(1)